Described are methods for reducing the formation of amphetamine carbamate and amphetacarbamate in transdermal amphetamine compositions, compositions with low levels of amphetacarbamate, and methods using such compositions for transdermal delivery of amphetamine.

A pramipexole transdermal patch for treatment of neurological disorders including Parkinson's disease that may be administered on a daily basis. The pramipexole transdermal patch of the present invention preferably comprises a drug-containing layer that comprises pramipexole or a pharmaceutically acceptable salt thereof at 2% to about 15% by weight of the drug-containing layer and at least two acrylic polymers wherein each polymer may further comprise carboxyl and/or hydroxyl functional groups. The pramipexole transdermal patch of the present invention may further comprise two or more permeation enhancers with combined pramipexole solubility of great than 50 mg/mL.

The present invention provides a gel patch having a paste layer on a support, wherein the paste layer comprising ketoprofen or a pharmaceutically acceptable salt thereof, propylene glycol, 1-menthol, and water, wherein the mass of propylene glycol in the paste layer is 3-fold the mass of ketoprofen or less, and wherein the content of 1-menthol based on a total mass of the paste layer is 0.1 to 0.5 mass %.

The present invention relates to transdermal devices comprising prodrugs of anti-pyretic, analgesic, or anti-inflammatory molecules, methods of making such devices, and methods of use thereof for treating, preventing, minimizing, and/or diminishing fever or pain.

The invention enables more efficient CTL induction by applying a transdermal preparation containing a WT1 protein-derived cancer antigen peptide and an ether-type additive, which is liquid at 20° C., to a WT1 protein-derived cancer antigen peptide. The ether-type additive is represented by the formula (1): R.sup.1—O—R2 (1), wherein R.sup.1 is a hydrocarbon group having 8-24 carbon atoms, and R.sup.2 is a group represented by the formula (2):

##STR00001##

or a group represented by the formula (3): —(CH.sub.2CH.sub.2O).sub.mH (3), wherein m is an integer of 1-18.

A method for suppressing a plasma concentration of an asenapine metabolite includes applying to a subject a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer includes asenapine and/or a pharmaceutically acceptable salt thereof, and an adhesive base agent.

The present disclosure relates to compositions, methods of use and methods of manufacturing of transdermal delivery systems, patches, vehicles and devices including an iontophoretic transdermal delivery system, patch, vehicle or device used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

An object is to provide an adhesive patch that is excellent in both percutaneous absorbability of a drug and adhesiveness to the skin. An adhesive patch of the present invention includes a backing and an adhesive layer integrally laminated on one side of the backing, the adhesive layer including a drug, levulinic acid, and an acrylic adhesive including an acrylic polymer (A) containing a vinyl-based monomer (I) moiety having a solubility parameter of 9 (cal/cm.sup.3).sup.1/2 or more. According to the present invention, it is possible to provide an adhesive patch that is excellent in both percutaneous absorbability of a drug and adhesiveness to the skin.

The present disclosure relates to the to the transdermal administration of nabilone and cannabinoids and derivatives of these compounds, for the treatment and/or prevention and/or control of medical conditions.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.